Atopic Dermatitis

The trial results indicated 3 significant improvements across all AHFD subtypes with dupilumab treatment compared to placebo.

Significant improvements were observed in EASI scores across all anatomical regions, regardless of patient age or specific body region.

Lawrence Eichenfield, MD, discusses the numerous limitations of current topical treatments for atopic dermatitis (AD), their impact on patient management, adherence, and quality of life, the common obstacles patients face in achieving adequate disease control with these therapies, and compares ruxolitinib cream as a nonsteroidal monotherapy alternative.

Learn more about the in-depth topics covered in the May 2024 supplement of Dermatology Times.

Supportive data for roflumilast in adults and children 6 years of age and older stems from the INTEGUMENT studies.

Misinformation regarding the use of corticosteroids remains persistent and may have implications on patient care.

A 5-expert panel continues their conversation on atopic dermatitis, discussing patient-centered care and key takeaways.

Results of a recent study show RECAP's impact on adult Asian patients with AD.

Scassellati Sforzolini discusses the significance of Galderma’s nemolizumab receiving 4 additional filing acceptances for prurigo nodularis and atopic dermatitis.

Researchers found that abrocitinib demonstrated rapid, sustained, and deep improvements in several important domains of itch-dominant AD.

A 5-expert panel continues their conversation on atopic dermatitis, exploring beyond steroids and addressing unmet needs.

5 experts share insights on long-term safety, efficacy, demographic variances, and more in pediatric AD.

Patients with AD experienced significant impacts to disease severity, disease control, and quality of life regardless of lesion location count.

A poster from the 2024 American Psychiatric Association Annual Meeting delved into the relationship between MDD and various dermatologic conditions.

Leading dermatologists explore key benchmarks, emerging trends, personalized medicine approaches, and more in atopic dermatitis.

Dr. Matthew J. Zirwas, evaluates a 45-year-old woman with worsening, highly itchy dermatitis on her hands and arms, notably her fingertips. He addresses management strategies for her condition, which has deteriorated over four months, leading to painful fissures

Matthew J. Zirwas, MD, , presents a complex case study of a 63-year-old male patient with atopic dermatitis presenting as a chronic, severe pruritic rash on his back, upper arms, and upper thighs. His condition has persisted consistently for the past three months despite a history of intermittent occurrences over several years.

A prebiotic cleanser and moisturizer regimen not only significantly alleviated the severity of atopic dermatitis and xerosis, but also uncovered crucial differences in symptom experiences.

The awarded grant will span a total of 3 years.

Following treatment, 17.5% and 13% of patients reported residual depressive and anxiety symptoms.

A 5-expert panel delves into atopic dermatitis guidelines and recommendations and recent studies to make note of.

ASLAN Pharmaceuticals presented new data this morning, including a 90% EASI score reduction.

Brian Kim, MD, had an unexpected attendee at one of his AAD sessions and delves into what's new, what's now, and what's next in atopic dermatitis management.

The new research will compare eblasakimab to dupilumab and lebrikizumab.

A recent survey showed education, shared decision-making, and addressing mental health concerns and financial burdens are key priorities in optimizing care.